Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Susan Seymore"'
Autor:
James A. Simon, Richard A. Anderson, Elizabeth Ballantyne, James Bolognese, Cecilia Caetano, Hadine Joffe, Mary Kerr, Nick Panay, Christian Seitz, Susan Seymore, Mike Trower, Lineke Zuurman, Steve Pawsey
Publikováno v:
Simon, J A, Anderson, R A, Ballantyne, E, Bolognese, J, Caetano, C, Joffe, H, Kerr, M, Panay, N, Seitz, C, Seymore, S, Trower, M, Zuurman, L & Pawsey, S 2023, ' Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1) ', Menopause . https://doi.org/10.1097/GME.0000000000002138
Objective Neurokinin (NK)-3 and NK-1 receptors have been implicated in the etiology of vasomotor symptoms (VMS) and sleep disturbances associated with menopause. This phase 2b, adaptive, dose-range finding study aimed to assess the efficacy and safet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc9f531434258a66ce71f536338a9fd7
https://www.pure.ed.ac.uk/ws/files/327901912/Efficacy_and_safety_of_elinzanetant_a_selective.146.pdf
https://www.pure.ed.ac.uk/ws/files/327901912/Efficacy_and_safety_of_elinzanetant_a_selective.146.pdf
Autor:
Steve Pawsey, Mike Trower, Hadine Joffe, Elizabeth Ballantyne, Richard A. Anderson, Susan Seymore, Mary Kerr, James A. Simon
Publikováno v:
Journal of the Endocrine Society
Introduction: Vasomotor symptoms (VMS), caused by declining estrogen in menopausal women, are common and debilitating. Hormone therapy is effective in many women but carries risks and may be contraindicated. Biological and clinical evidence shows a m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab427f598ee79dfd3373d55a18248704
https://doi.org/10.1210/jendso/bvaa046.2071
https://doi.org/10.1210/jendso/bvaa046.2071
